The protein encoded by this gene belongs to the CD28 and CTLA-4 cell-surface receptor family. It forms homodimers and plays an important role in cell-cell signaling, immune responses, and regulation of cell proliferation.
Compared to wild-type naïve T cells, ICOS-/- T cells activated with plate-bound anti-CD3 have reduced proliferation and IL-2 secretion. The defect in proliferation can be rescued by addition of IL-2 to the culture, suggesting the proliferative defect is due either to ICOS-mediated IL-2 secretion or the activation of similar signaling pathways between ICOS and IL-2. In terms of Th1 and Th2 cytokine secretion, ICOS-/- CD4+ T cell activated in vitro have reduced IL-4 secretion, but similar IFN-g secretion. Similarly, CD4+ T cells purified from ICOS-/- mice immunized with the protein keyhole limpet hemocyanin (KLH) in alum or Complete Freund's Adjuvant have attenuated IL-4 secretion, but similar IFN-g and IL-5 secretion when recalled with KLH.
These data are similar to an airway hypersensitivity model showing similar IL-5 secretion, but reduced IL-4 secretion in response to sensitization with Ova protein, indicating a defect in Th2 cytokine secretion, but not a defect in Th1 differentiation as both IL-4 and IL-5 are Th2-associated cytokines. In agreement with reduced Th2 responses, ICOS-/- mice have reduced germinal center formation and IgG1 and IgE antibody titers in response to immunization.
Ipilimumab patients expressed increased ICOS+ T cells in tumor tissues and blood. The increase served as a pharmacodynamic biomarker of anti-CTLA-4 treatment. In wild-type C57BL/6 mice, anti-CTLA-4 treatment resulted in tumor rejection in 80 to 90% of subjects, but in gene-targeted mice that were deficient for either ICOS or its ligand, the efficacy was less than 50%. An agonistic stimulus for the ICOS pathway during anti-CTLA-4 therapy resulted in an increase in efficacy that was about four to five times as large as that of control treatments. As of 2015 antibodies for ICOS were not available for clinical testing.
^Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I et al. (Jan 1999). "ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28". Nature397 (6716): 263–6. doi:10.1038/16717. PMID9930702.
^Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T et al. (Dec 1999). "T-cell co-stimulation through B7RP-1 and ICOS". Nature402 (6763): 827–32. doi:10.1038/45582. PMID10617205.
Flesch IE (2003). "Inducible costimulator (ICOS)". Journal of Biological Regulators and Homeostatic Agents16 (3): 214–6. PMID12456021.
Shilling RA, Bandukwala HS, Sperling AI (Oct 2006). "Regulation of T:B cell interactions by the inducible costimulator molecule: does ICOS "induce" disease?". Clinical Immunology121 (1): 13–8. doi:10.1016/j.clim.2006.04.574. PMID16790364.
Ling V, Wu PW, Finnerty HF, Bean KM, Spaulding V, Fouser LA et al. (Feb 2000). "Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor". Journal of Immunology164 (4): 1653–7. doi:10.4049/jimmunol.164.4.1653. PMID10657606.
Aicher A, Hayden-Ledbetter M, Brady WA, Pezzutto A, Richter G, Magaletti D et al. (May 2000). "Characterization of human inducible costimulator ligand expression and function". Journal of Immunology164 (9): 4689–96. doi:10.4049/jimmunol.164.9.4689. PMID10779774.
Machado RD, Pauciulo MW, Fretwell N, Veal C, Thomson JR, Vilariño Güell C et al. (Sep 2000). "A physical and transcript map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension. The International PPH Consortium". Genomics68 (2): 220–8. doi:10.1006/geno.2000.6291. PMID10964520.
Tezuka K, Tsuji T, Hirano D, Tamatani T, Sakamaki K, Kobayashi Y et al. (Sep 2000). "Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule, related to the CD28/CTLA4 family". Biochemical and Biophysical Research Communications276 (1): 335–45. doi:10.1006/bbrc.2000.3466. PMID11006126.
Wang S, Zhu G, Chapoval AI, Dong H, Tamada K, Ni J et al. (Oct 2000). "Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS". Blood96 (8): 2808–13. PMID11023515.
Ling V, Wu PW, Finnerty HF, Agostino MJ, Graham JR, Chen S et al. (Dec 2001). "Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches". Genomics78 (3): 155–68. doi:10.1006/geno.2001.6655. PMID11735222.
Lee YH, Ji JD, Sohn J, Song GG (2002). "Polymorphsims of CTLA-4 exon 1 +49, CTLA-4 promoter -318 and Fas promoter -670 in spondyloarthropathies". Clinical Rheumatology20 (6): 420–2. doi:10.1007/s100670170007. PMID11771526.
Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Dräger R et al. (Mar 2003). "Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency". Nature Immunology4 (3): 261–8. doi:10.1038/ni902. PMID12577056.